175250 — Icure Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Icure Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	90,144	64,283	59,367	56,806	69,207
Cost of Revenue
Gross Profit	18,097	-4,659	-5,580	1,298	7,607
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	100,648	96,692	87,511	81,702	95,315
Operating Profit	-10,504	-32,409	-28,144	-24,895	-26,108
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-11,498	-38,835	-43,090	-32,525	-388
Provision for Income Taxes
Net Income After Taxes	-12,150	-38,384	-42,549	-32,299	24.7
Minority Interest
Net Income Before Extraordinary Items
Net Income	-12,614	-38,167	-41,766	-31,420	1,049
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-12,614	-38,167	-41,766	-31,420	1,049
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-664	-1,423	-1,753	-799	-365
Dividends per Share